Showing 1 - 4 results of 4 for search 'M. Andreeff', query time: 0.02s Refine Results
  1. 1
    P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA

    P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEM... by A. Bazinet, T. Kadia, N. Short, G. Borthakur, S. Wang, S. Loghavi, J. Jorgensen, K. Patel, C. DiNardo, N. Daver, Y. Alvarado, F. Haddad, S. Pierce, M. Andreeff, E. Jabbour, M. Konopleva, H. Kantarjian, F. Ravandi

    Published 2022-06-01
    Get full text
    Article
  2. 2
    S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY

    S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY by M. Yilmaz, M. Muftuoglu, H. Kantarjian, C. DiNardo, T. Kadia, G. Borthakur, N. Pemmaraju, N. Short, Y. Alvarado, A. Maiti, L. Masarova, G. Montalban Bravo, S. Loghavi, K. Patel, S. Kornblau, E. Jabbour, G. Garcia-Manero, M. Andreeff, N. Daver

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

    P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA by J. Senapati, J. Ishizawa, H. A. Abbas, S. Loghavi, G. Borthakur, G. C. Issa, S. I. Dara, R. Pourebrahim, N. Daver, E. J. Jabbour, S. M. Kornblau, N. Pemmaraju, G. Garcia-Manero, F. Ravandi, M. Muftuoglu, J. Khoury, C. DiNardo, M. Andreeff

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

    P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA by A. Bazinet, E. Jabbour, H. Kantarjian, K. Chien, C. DiNardo, M. Ohanian, N. Daver, R. Kanagal-Shamanna, T. Kadia, K. Takahashi, L. Masarova, N. Short, Y. Alvarado, P. Thompson, G. Montalban-Bravo, M. Yilmaz, F. Ravandi, M. Konopleva, M. Andreeff, S. Kornblau, N. Pemmaraju, D. Hammond, H. Schneider, B. Mirabella, G. Garcia-Manero

    Published 2022-06-01
    Get full text
    Article

Search Tools: